611225-63-9

Basic information

• Product Name: 2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester
• Synonyms: 2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester;tert-butyl 4-(4-(methylamino)-3-nitrophenoxy)picolinate
• CAS NO: 611225-63-9
• Molecular Formula: C₁₇H₁₉N₃O₅
• Molecular Weight: 345.35
• Product Categories: API intermediates
• Mol File: 611225-63-9.mol

Chemical Properties

• Melting Point: 195 °C
• Boiling Point: 497.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.269±0.06 g/cm3(Predicted)
• PKA: 0.94±0.10(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester(611225-63-9)
• EPA Substance Registry System: 2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester(611225-63-9)

Safety Data

• Hazardous Substances Data: 611225-63-9(Hazardous Substances Data)

Usage

Uses

Used in Medicinal and Pharmaceutical Research:
2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester is used as a research compound for its potential applications in the development of new drugs and pharmaceuticals. Its unique chemical structure and properties allow it to interact with biological systems, making it a valuable tool in the study of various diseases and conditions.
Used as an Intermediate in Chemical Production:
In the chemical industry, 2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester serves as an intermediate in the synthesis of various other compounds. Its versatility and reactivity make it a useful building block for the creation of new chemical entities with potential applications in various fields.
Used in Drug Discovery:
2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester is utilized in drug discovery as a starting material or a key component in the development of novel therapeutic agents. Its unique structure and properties enable it to be modified and optimized for specific biological targets, leading to the discovery of new drugs with improved efficacy and safety profiles.
Used in Material Sciences:
In the field of material sciences, 2-Pyridinecarboxylic acid, 4-[4-(methylamino)-3-nitrophenoxy]-, 1,1-dimethylethyl ester is employed for its potential applications in the development of new materials with unique properties. Its chemical structure and reactivity make it a promising candidate for the creation of advanced materials with applications in various industries, such as electronics, energy, and environmental protection.

Upstream product

• 220000-86-2 tert-butyl 4-chloropyridine-2-carboxylate 
• 611225-60-6 tert-butyl 4-(4-amino-3-nitrophenoxy)picolinate 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 611225-62-8 tert-butyl 4-[3-nitro-4-(2,2,2-trifluoro-N-methylacetylamino) phenoxy]pyridine-2-carboxylate 
• 610-81-1 4-hydroxy-2-nitroaniline 

Downstream Products

• 611226-09-6 4-(4-(methylamino)-3-nitrophenoxy)pyridine-2-carboxylic acid 
• 850713-40-5 C₁₃H₁₀N₆O₄ 
• 850713-41-6 tert-butyl (4-(4-(methylamino)-3-nitrophenoxy)pyridin-2-yl)carbamate 
• 850713-43-8 N-(4-(3-amino-4-(methylamino)phenoxy)pyridin-2-yl)acetamide 
• 850635-69-7 4-(4-(methylamino)-3-nitrophenoxy)pyridin-2-amine 

Relevant articles and documents

Discovery of RAF265: A Potent mut-B-RAF inhibitor for the treatment of metastatic melanoma

Abrogation of errant signaling along the MAPK pathway through the inhibition of B-RAF kinase is a validated approach for the treatment of pathway-dependent cancers. We report the development of imidazo-benzimidazoles as potent B-RAF inhibitors. Robust in

Design and synthesis of orally bioavailable benzimidazole reverse amides as pan RAF kinase inhibitors

Benzimidazole reverse amides were designed and synthesized as Pan RAF kinase inhibitors. Investigation of the structure-activity relationship of the compounds revealed that they were potent in vitro and exhibited desirable in vivo properties.

SOLID FORMS OF A RAF KINASE INHIBITOR

The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the sa

Design and synthesis of orally bioavailable benzimidazoles as raf kinase inhibitors

A series of arylaminobenzimidazoles was designed and synthesized as Raf kinase inhibitors. Exploration of the structure-activity relationship resulted in compounds that are potent in vitro and show desirable in vivo properties.

FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS

Formulations are provided, comprising: a compound of Formula (I), a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture

SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF

Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of { 1 -methyl-5- [2-(5-trifluoromethyl- 1 H-imidazol-2-yl)-pyridin-4-yloxy] - 1 H-benzoimidazol-2-yl } -(4- trifluoromethyl-phenyl)amine. Compositions and formulations including such

Substituted benzimidazoles and methods of preparation

Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined herein

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.